Absolute Quantitation of Myocardial Blood Flow in Human Subjects With or Without Myocardial Ischemia Using Dynamic Flurpiridaz F 18 PET
Absolute quantitation of myocardial blood flow (MBF) by PET is an established method of analyzing coronary artery disease (CAD) but subject to the various shortcomings of available radiotracers. Flurpiridaz F 18 is a novel PET radiotracer that exhibits properties of an ideal tracer. A new absolute p...
Saved in:
Published in | Journal of Nuclear Medicine Vol. 55; no. 9; pp. 1438 - 1444 |
---|---|
Main Authors | , , , , |
Format | Journal Article |
Language | English |
Published |
United States
Society of Nuclear Medicine
01.09.2014
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Absolute quantitation of myocardial blood flow (MBF) by PET is an established method of analyzing coronary artery disease (CAD) but subject to the various shortcomings of available radiotracers. Flurpiridaz F 18 is a novel PET radiotracer that exhibits properties of an ideal tracer.
A new absolute perfusion quantitation method with flurpiridaz was developed, taking advantage of the early kinetics and high first-pass extraction by the myocardium of this radiotracer, and the first-in-human measurements of MBF performed in 7 healthy subjects and 8 patients with documented CAD. PET images with time-activity curves were acquired at rest and during adenosine stress.
In healthy subjects, regional MBF between coronary artery territories did not differ significantly, leading to a mean global MBF of 0.73 mL/min/g at rest and 2.53 mL/min/g during stress, with a mean global myocardial flow reserve (MFR) of 3.70. CAD vascular territories with <50% stenosis demonstrated a mean MBF of 0.73 at rest and 2.02 during stress, leading to a mean MFR of 2.97. CAD vascular territories with ≥50% stenosis exhibited a mean MBF of 0.86 at rest and 1.43 during stress, leading to a mean MFR of 1.86. Differences in stress MBF and MFR between normal and CAD territories, as well as between <50% and ≥50% stenosis vascular territories, were significant (P < 0.01).
Absolute quantitation of MBF in humans with the novel PET radiotracer flurpiridaz is feasible over a wide range of cardiac flow in the presence or absence of stress-inducible myocardial ischemia. The significant decrease in stress MBF and ensuing MFR in CAD territories allows a clear distinction between vascular territories exhibiting stress-inducible myocardial ischemia and those with normal perfusion. |
---|---|
AbstractList | Absolute quantitation of myocardial blood flow (MBF) by PET is an established method of analyzing coronary artery disease (CAD) but subject to the various shortcomings of available radiotracers. Flurpiridaz F 18 is a novel PET radiotracer that exhibits properties of an ideal tracer.
A new absolute perfusion quantitation method with flurpiridaz was developed, taking advantage of the early kinetics and high first-pass extraction by the myocardium of this radiotracer, and the first-in-human measurements of MBF performed in 7 healthy subjects and 8 patients with documented CAD. PET images with time-activity curves were acquired at rest and during adenosine stress.
In healthy subjects, regional MBF between coronary artery territories did not differ significantly, leading to a mean global MBF of 0.73 mL/min/g at rest and 2.53 mL/min/g during stress, with a mean global myocardial flow reserve (MFR) of 3.70. CAD vascular territories with <50% stenosis demonstrated a mean MBF of 0.73 at rest and 2.02 during stress, leading to a mean MFR of 2.97. CAD vascular territories with ≥50% stenosis exhibited a mean MBF of 0.86 at rest and 1.43 during stress, leading to a mean MFR of 1.86. Differences in stress MBF and MFR between normal and CAD territories, as well as between <50% and ≥50% stenosis vascular territories, were significant (P < 0.01).
Absolute quantitation of MBF in humans with the novel PET radiotracer flurpiridaz is feasible over a wide range of cardiac flow in the presence or absence of stress-inducible myocardial ischemia. The significant decrease in stress MBF and ensuing MFR in CAD territories allows a clear distinction between vascular territories exhibiting stress-inducible myocardial ischemia and those with normal perfusion. Absolute quantitation of myocardial blood flow (MBF) by PET is an established method of analyzing coronary artery disease (CAD) but subject to the various shortcomings of available radiotracers. Flurpiridaz F 18 is a novel PET radiotracer that exhibits properties of an ideal tracer. A new absolute perfusion quantitation method with flurpiridaz was developed, taking advantage of the early kinetics and high first-pass extraction by the myocardium of this radiotracer, and the first-in-human measurements of MBF performed in 7 healthy subjects and 8 patients with documented CAD. PET images with time-activity curves were acquired at rest and during adenosine stress. In healthy subjects, regional MBF between coronary artery territories did not differ significantly, leading to a mean global MBF of 0.73 mL/min/g at rest and 2.53 mL/min/g during stress, with a mean global myocardial flow reserve (MFR) of 3.70. CAD vascular territories with <50% stenosis demonstrated a mean MBF of 0.73 at rest and 2.02 during stress, leading to a mean MFR of 2.97. CAD vascular territories with ≥50% stenosis exhibited a mean MBF of 0.86 at rest and 1.43 during stress, leading to a mean MFR of 1.86. Differences in stress MBF and MFR between normal and CAD territories, as well as between <50% and ≥50% stenosis vascular territories, were significant (P < 0.01). Absolute quantitation of MBF in humans with the novel PET radiotracer flurpiridaz is feasible over a wide range of cardiac flow in the presence or absence of stress-inducible myocardial ischemia. The significant decrease in stress MBF and ensuing MFR in CAD territories allows a clear distinction between vascular territories exhibiting stress-inducible myocardial ischemia and those with normal perfusion. Absolute quantitation of myocardial blood flow (MBF) by PET is an established method of analyzing coronary artery disease (CAD) but subject to the various shortcomings of available radiotracers. Flurpiridaz F 18 is a novel PET radiotracer that exhibits properties of an ideal tracer.UNLABELLEDAbsolute quantitation of myocardial blood flow (MBF) by PET is an established method of analyzing coronary artery disease (CAD) but subject to the various shortcomings of available radiotracers. Flurpiridaz F 18 is a novel PET radiotracer that exhibits properties of an ideal tracer.A new absolute perfusion quantitation method with flurpiridaz was developed, taking advantage of the early kinetics and high first-pass extraction by the myocardium of this radiotracer, and the first-in-human measurements of MBF performed in 7 healthy subjects and 8 patients with documented CAD. PET images with time-activity curves were acquired at rest and during adenosine stress.METHODSA new absolute perfusion quantitation method with flurpiridaz was developed, taking advantage of the early kinetics and high first-pass extraction by the myocardium of this radiotracer, and the first-in-human measurements of MBF performed in 7 healthy subjects and 8 patients with documented CAD. PET images with time-activity curves were acquired at rest and during adenosine stress.In healthy subjects, regional MBF between coronary artery territories did not differ significantly, leading to a mean global MBF of 0.73 mL/min/g at rest and 2.53 mL/min/g during stress, with a mean global myocardial flow reserve (MFR) of 3.70. CAD vascular territories with <50% stenosis demonstrated a mean MBF of 0.73 at rest and 2.02 during stress, leading to a mean MFR of 2.97. CAD vascular territories with ≥50% stenosis exhibited a mean MBF of 0.86 at rest and 1.43 during stress, leading to a mean MFR of 1.86. Differences in stress MBF and MFR between normal and CAD territories, as well as between <50% and ≥50% stenosis vascular territories, were significant (P < 0.01).RESULTSIn healthy subjects, regional MBF between coronary artery territories did not differ significantly, leading to a mean global MBF of 0.73 mL/min/g at rest and 2.53 mL/min/g during stress, with a mean global myocardial flow reserve (MFR) of 3.70. CAD vascular territories with <50% stenosis demonstrated a mean MBF of 0.73 at rest and 2.02 during stress, leading to a mean MFR of 2.97. CAD vascular territories with ≥50% stenosis exhibited a mean MBF of 0.86 at rest and 1.43 during stress, leading to a mean MFR of 1.86. Differences in stress MBF and MFR between normal and CAD territories, as well as between <50% and ≥50% stenosis vascular territories, were significant (P < 0.01).Absolute quantitation of MBF in humans with the novel PET radiotracer flurpiridaz is feasible over a wide range of cardiac flow in the presence or absence of stress-inducible myocardial ischemia. The significant decrease in stress MBF and ensuing MFR in CAD territories allows a clear distinction between vascular territories exhibiting stress-inducible myocardial ischemia and those with normal perfusion.CONCLUSIONAbsolute quantitation of MBF in humans with the novel PET radiotracer flurpiridaz is feasible over a wide range of cardiac flow in the presence or absence of stress-inducible myocardial ischemia. The significant decrease in stress MBF and ensuing MFR in CAD territories allows a clear distinction between vascular territories exhibiting stress-inducible myocardial ischemia and those with normal perfusion. Absolute quantitation of myocardial blood flow (MBF) by PET is an established method of analyzing coronary artery disease (CAD) but subject to the various shortcomings of available radiotracers. Flurpiridaz F 18 is a novel PET radiotracer that exhibits properties of an ideal tracer. A new absolute perfusion quantitation method with flurpiridaz was developed, taking advantage of the early kinetics and high first-pass extraction by the myocardium of this radiotracer, and the first-in-human measurements of MBF performed in 7 healthy subjects and 8 patients with documented CAD. PET images with time-activity curves were acquired at rest and during adenosine stress. In healthy subjects, regional MBF between coronary artery territories did not differ significantly, leading to a mean global MBF of 0.73 mL/min/g at rest and 2.53 mL/min/g during stress, with a mean global myocardial flow reserve (MFR) of 3.70. CAD vascular territories with 50% stenosis demonstrated a mean MBF of 0.73 at rest and 2.02 during stress, leading to a mean MFR of 2.97. CAD vascular territories with 50% stenosis exhibited a mean MBF of 0.86 at rest and 1.43 during stress, leading to a mean MFR of 1.86. Differences in stress MBF and MFR between normal and CAD territories, as well as between 50% and 50% stenosis vascular territories, were significant (P 0.01). Absolute quantitation of MBF in humans with the novel PET radiotracer flurpiridaz is feasible over a wide range of cardiac flow in the presence or absence of stress-inducible myocardial ischemia. The significant decrease in stress MBF and ensuing MFR in CAD territories allows a clear distinction between vascular territories exhibiting stress-inducible myocardial ischemia and those with normal perfusion. |
Author | Dahlbom, Magnus Czernin, Johannes Maddahi, Jamshid Huang, Sung-Cheng Packard, René R.S. |
Author_xml | – sequence: 1 givenname: René R.S. surname: Packard fullname: Packard, René R.S. – sequence: 2 givenname: Sung-Cheng surname: Huang fullname: Huang, Sung-Cheng – sequence: 3 givenname: Magnus surname: Dahlbom fullname: Dahlbom, Magnus – sequence: 4 givenname: Johannes surname: Czernin fullname: Czernin, Johannes – sequence: 5 givenname: Jamshid surname: Maddahi fullname: Maddahi, Jamshid |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/25071096$$D View this record in MEDLINE/PubMed |
BookMark | eNqNkc1uEzEUhS1URNPCA7BBltiwSbjXGdvjZSlNW6kIEK1gZ3kmHupoxk79IxReoK_NpEklVAmJ1dl851xdfUfkwAdvCXmNMGNKyPcrXwa7nCFWM6wQ1PwZmTDkaioE-3FAJoACp5wDPyRHKa0AQNR1_YIcMg5y5MWE3J80KfQlW_q1GJ9dNtkFT0NHP21Ca-LSmZ5-6ENY0kUfflHn6UUZjKffSrOybU70u8u3NMSHDCX_3btM7a0dnKE3yfmf9OPGm8G141CJaxfd0vymC4o1_XJ2_ZI870yf7Kt9HpObxdn16cX06vP55enJ1bStgOdpw8GCsNIIaLjqmLK8YbLjnZRKqfG7BqrOcKwVVjWrmMCus5KbxiDWssL5MXm3213HcFdsynpwqbV9b7wNJWmUNXCoFPwHygWAqhnfom-foKtQoh8f2VI450w93H6zp0ozetPr6AYTN_rRxgjIHdDGkFK0nW73QnI0rtcIeutd77zr0bveeR-b-KT5OP7vzh_IWrAo |
CODEN | JNMEAQ |
CitedBy_id | crossref_primary_10_1007_s12350_020_02034_2 crossref_primary_10_1016_j_ccl_2015_07_013 crossref_primary_10_1007_s12350_023_03239_x crossref_primary_10_1007_s12350_021_02873_7 crossref_primary_10_1002_mp_12398 crossref_primary_10_1007_s00259_016_3480_8 crossref_primary_10_1007_s12350_016_0763_1 crossref_primary_10_1007_s10554_018_1330_4 crossref_primary_10_1016_j_ccl_2023_01_003 crossref_primary_10_1007_s00259_021_05643_2 crossref_primary_10_1053_j_semnuclmed_2014_06_011 crossref_primary_10_2967_jnumed_115_164111 crossref_primary_10_1093_ehjci_jeab267 crossref_primary_10_1016_j_pcad_2015_01_001 crossref_primary_10_1007_s12350_015_0199_z crossref_primary_10_1016_j_nuclcard_2024_101834 crossref_primary_10_1002_jmri_25604 crossref_primary_10_1002_ppap_201500099 crossref_primary_10_1007_s12350_020_02421_9 crossref_primary_10_1007_s12350_019_01694_z crossref_primary_10_1007_s00259_016_3317_5 crossref_primary_10_1007_s11886_020_01368_0 crossref_primary_10_3389_fcvm_2022_919719 crossref_primary_10_1111_cpf_12708 crossref_primary_10_1161_CIRCRESAHA_116_307898 crossref_primary_10_1007_s12149_021_01601_y crossref_primary_10_1109_TRPMS_2020_3010844 crossref_primary_10_1038_s44161_024_00587_w crossref_primary_10_1007_s00259_015_3101_y crossref_primary_10_1007_s00259_025_07174_6 crossref_primary_10_2967_jnumed_120_252007 crossref_primary_10_1007_s12350_016_0513_4 crossref_primary_10_1007_s12350_015_0300_7 crossref_primary_10_1007_s12350_020_02434_4 crossref_primary_10_1007_s10554_018_1469_z crossref_primary_10_1007_s12350_022_02968_9 crossref_primary_10_1016_j_jjcc_2017_03_002 crossref_primary_10_17996_anc_18_00052 crossref_primary_10_1161_CIRCULATIONAHA_115_018089 crossref_primary_10_1007_s12350_017_1140_4 crossref_primary_10_3389_fphar_2015_00227 crossref_primary_10_1007_s10741_017_9620_9 crossref_primary_10_1007_s12350_017_0909_9 crossref_primary_10_1007_s12149_017_1171_6 crossref_primary_10_1007_s11886_022_01713_5 crossref_primary_10_1007_s12350_020_02335_6 crossref_primary_10_1016_j_cpet_2020_09_004 crossref_primary_10_1016_j_tcm_2019_02_007 crossref_primary_10_1007_s12181_018_0266_1 crossref_primary_10_1155_2017_5246853 crossref_primary_10_1007_s12350_017_1131_5 crossref_primary_10_1007_s40336_018_0263_1 crossref_primary_10_1007_s00259_017_3684_6 crossref_primary_10_1016_j_nuclcard_2024_102072 |
Cites_doi | 10.1016/j.nuclcard.2007.07.009 10.1016/j.nuclcard.2007.07.008 10.1161/CIRCIMAGING.108.815423 10.2967/jnumed.110.083196 10.2967/jnumed.111.092528 10.1016/j.jacc.2012.11.022 10.1016/j.nuclcard.2007.06.120 10.1016/j.jcmg.2010.04.007 10.1007/s12350-011-9491-8 10.1016/j.nuclcard.2004.04.005 10.1161/CIRCULATIONAHA.109.915009 10.1161/CIRCULATIONAHA.111.050427 10.2967/jnumed.110.081828 10.2967/jnumed.108.054395 10.2967/jnumed.107.044727 10.1161/CIRCULATIONAHA.108.797761 10.1016/j.jacc.2009.02.069 10.1016/j.jacc.2011.01.065 10.1007/s12350-012-9588-8 10.1016/j.jcmg.2011.12.014 10.1161/01.CIR.88.1.62 |
ContentType | Journal Article |
Copyright | 2014 by the Society of Nuclear Medicine and Molecular Imaging, Inc. Copyright Society of Nuclear Medicine Sep 1, 2014 |
Copyright_xml | – notice: 2014 by the Society of Nuclear Medicine and Molecular Imaging, Inc. – notice: Copyright Society of Nuclear Medicine Sep 1, 2014 |
DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 4T- 8FD FR3 K9. M7Z NAPCQ P64 7X8 7QO |
DOI | 10.2967/jnumed.114.141093 |
DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed Docstoc Technology Research Database Engineering Research Database ProQuest Health & Medical Complete (Alumni) Biochemistry Abstracts 1 Nursing & Allied Health Premium Biotechnology and BioEngineering Abstracts MEDLINE - Academic Biotechnology Research Abstracts |
DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Nursing & Allied Health Premium Technology Research Database Docstoc Biochemistry Abstracts 1 ProQuest Health & Medical Complete (Alumni) Engineering Research Database Biotechnology and BioEngineering Abstracts MEDLINE - Academic Biotechnology Research Abstracts |
DatabaseTitleList | MEDLINE Nursing & Allied Health Premium MEDLINE - Academic Engineering Research Database |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 2159-662X 1535-5667 |
EndPage | 1444 |
ExternalDocumentID | 3429190251 25071096 10_2967_jnumed_114_141093 |
Genre | Research Support, Non-U.S. Gov't Journal Article Research Support, N.I.H., Extramural Feature |
GrantInformation_xml | – fundername: NHLBI NIH HHS grantid: T32 HL007895 |
GroupedDBID | 123 18M 41~ 5VS 96U AAYXX ACGFO AEGXH AIAGR ALMA_UNASSIGNED_HOLDINGS CITATION GX1 N9A RHI TSM U5U W8F --- -~X .55 .GJ 29L 2WC 3O- 53G 5RE 7RV 7X7 88E 88I 8AF 8AO 8FE 8FG 8FH 8FI 8FJ 8R4 8R5 8WZ A6W ABEFU ABSQV ABUWG ACGOD ACIWK ACPRK ADDZX ADMOG AENEX AFFNX AFKRA AFOSN AFRAH AHMBA AI. ALIPV ARAPS AZQEC BBNVY BENPR BGLVJ BHPHI BKEYQ BPHCQ BVXVI CCPQU CGR CS3 CUY CVF DIK DU5 DWQXO E3Z EBD EBS ECM EIF EJD EMOBN EX3 F5P F9R FYUFA GNUQQ H13 HCIFZ HMCUK I-F IL9 INIJC J5H KQ8 L7B LK8 M1P M2P M2Q M7P N4W NAPCQ NPM OK1 P2P P62 PHGZT PQQKQ PROAC PSQYO Q2X R0Z RNS RWL S0X SJN SV3 TAE TR2 TUS UKHRP VH1 WH7 WOQ WOW X7M YHG YQJ ZGI ZXP 4T- 8FD FR3 K9. M7Z P64 7X8 7QO |
ID | FETCH-LOGICAL-c405t-b50e06e7a60b59f29e5b27f5f77999688b04fa518914824261ffe75aba1187413 |
ISSN | 0161-5505 1535-5667 |
IngestDate | Fri Jul 11 09:32:46 EDT 2025 Fri Jul 11 08:12:35 EDT 2025 Mon Jun 30 10:44:37 EDT 2025 Thu Apr 03 07:09:07 EDT 2025 Tue Jul 01 01:45:11 EDT 2025 Thu Apr 24 22:54:18 EDT 2025 |
IsDoiOpenAccess | false |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 9 |
Keywords | MBF MFR flurpiridaz human PET |
Language | English |
License | 2014 by the Society of Nuclear Medicine and Molecular Imaging, Inc. |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-c405t-b50e06e7a60b59f29e5b27f5f77999688b04fa518914824261ffe75aba1187413 |
Notes | SourceType-Scholarly Journals-1 ObjectType-Feature-1 content type line 14 ObjectType-Article-1 ObjectType-Feature-2 content type line 23 |
OpenAccessLink | http://jnm.snmjournals.org/content/55/9/1438.full.pdf |
PMID | 25071096 |
PQID | 1561352941 |
PQPubID | 40808 |
PageCount | 7 |
ParticipantIDs | proquest_miscellaneous_1780504901 proquest_miscellaneous_1560098251 proquest_journals_1561352941 pubmed_primary_25071096 crossref_citationtrail_10_2967_jnumed_114_141093 crossref_primary_10_2967_jnumed_114_141093 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | 2014-09-00 2014-Sep 20140901 |
PublicationDateYYYYMMDD | 2014-09-01 |
PublicationDate_xml | – month: 09 year: 2014 text: 2014-09-00 |
PublicationDecade | 2010 |
PublicationPlace | United States |
PublicationPlace_xml | – name: United States – name: New York |
PublicationTitle | Journal of Nuclear Medicine |
PublicationTitleAlternate | J Nucl Med |
PublicationYear | 2014 |
Publisher | Society of Nuclear Medicine |
Publisher_xml | – name: Society of Nuclear Medicine |
References | 2021051712064055000_55.9.1438.20 2021051712064055000_55.9.1438.13 2021051712064055000_55.9.1438.12 2021051712064055000_55.9.1438.11 2021051712064055000_55.9.1438.10 2021051712064055000_55.9.1438.21 Johnson (2021051712064055000_55.9.1438.19) 2012; 5 2021051712064055000_55.9.1438.1 2021051712064055000_55.9.1438.2 2021051712064055000_55.9.1438.3 2021051712064055000_55.9.1438.4 2021051712064055000_55.9.1438.5 2021051712064055000_55.9.1438.17 2021051712064055000_55.9.1438.6 2021051712064055000_55.9.1438.16 2021051712064055000_55.9.1438.7 2021051712064055000_55.9.1438.15 2021051712064055000_55.9.1438.8 2021051712064055000_55.9.1438.14 2021051712064055000_55.9.1438.9 Nagamachi (2021051712064055000_55.9.1438.22) 1996; 37 2021051712064055000_55.9.1438.18 22007073 - Circulation. 2011 Nov 15;124(20):2215-24 21498538 - J Nucl Med. 2011 May;52(5):726-32 20541718 - JACC Cardiovasc Imaging. 2010 Jun;3(6):623-40 17826322 - J Nucl Cardiol. 2007 Sep-Oct;14(5):688-97 8862296 - J Nucl Med. 1996 Oct;37(10):1626-31 19808572 - Circ Cardiovasc Imaging. 2009 Mar;2(2):77-84 19380625 - Circulation. 2009 May 5;119(17):2333-42 23265345 - J Am Coll Cardiol. 2013 Jan 29;61(4):469-77 19573732 - J Am Coll Cardiol. 2009 Jul 7;54(2):150-6 18022105 - J Nucl Cardiol. 2007 Nov-Dec;14(6):789-98 18022104 - J Nucl Cardiol. 2007 Nov-Dec;14(6):782-8 8319357 - Circulation. 1993 Jul;88(1):62-9 20660808 - Circulation. 2010 Aug 10;122(6):603-13 19164219 - J Nucl Med. 2009 Feb;50(2):214-9 21441533 - J Nucl Med. 2011 Apr;52(4):617-24 22733534 - J Nucl Cardiol. 2012 Oct;19(5):1044-59 15295413 - J Nucl Cardiol. 2004 Jul-Aug;11(4):440-9 22498334 - JACC Cardiovasc Imaging. 2012 Apr;5(4):430-40 21849402 - J Nucl Med. 2011 Sep;52(9):1490-8 18344426 - J Nucl Med. 2008 Apr;49(4):630-6 21816311 - J Am Coll Cardiol. 2011 Aug 9;58(7):740-8 22259007 - J Nucl Cardiol. 2012 Feb;19 Suppl 1:S30-7 |
References_xml | – ident: 2021051712064055000_55.9.1438.3 doi: 10.1016/j.nuclcard.2007.07.009 – ident: 2021051712064055000_55.9.1438.4 doi: 10.1016/j.nuclcard.2007.07.008 – ident: 2021051712064055000_55.9.1438.8 doi: 10.1161/CIRCIMAGING.108.815423 – ident: 2021051712064055000_55.9.1438.7 doi: 10.2967/jnumed.110.083196 – ident: 2021051712064055000_55.9.1438.9 doi: 10.2967/jnumed.111.092528 – ident: 2021051712064055000_55.9.1438.10 doi: 10.1016/j.jacc.2012.11.022 – ident: 2021051712064055000_55.9.1438.11 doi: 10.1016/j.nuclcard.2007.06.120 – ident: 2021051712064055000_55.9.1438.1 doi: 10.1016/j.jcmg.2010.04.007 – ident: 2021051712064055000_55.9.1438.2 doi: 10.1007/s12350-011-9491-8 – ident: 2021051712064055000_55.9.1438.15 doi: 10.1016/j.nuclcard.2004.04.005 – volume: 37 start-page: 1626 year: 1996 ident: 2021051712064055000_55.9.1438.22 article-title: Reproducibility of measurements of regional resting and hyperemic myocardial blood flow assessed with PET publication-title: J Nucl Med. – ident: 2021051712064055000_55.9.1438.12 doi: 10.1161/CIRCULATIONAHA.109.915009 – ident: 2021051712064055000_55.9.1438.18 doi: 10.1161/CIRCULATIONAHA.111.050427 – ident: 2021051712064055000_55.9.1438.16 doi: 10.2967/jnumed.110.081828 – ident: 2021051712064055000_55.9.1438.13 doi: 10.2967/jnumed.108.054395 – ident: 2021051712064055000_55.9.1438.5 doi: 10.2967/jnumed.107.044727 – ident: 2021051712064055000_55.9.1438.6 doi: 10.1161/CIRCULATIONAHA.108.797761 – ident: 2021051712064055000_55.9.1438.14 doi: 10.1016/j.jacc.2009.02.069 – ident: 2021051712064055000_55.9.1438.17 doi: 10.1016/j.jacc.2011.01.065 – ident: 2021051712064055000_55.9.1438.20 doi: 10.1007/s12350-012-9588-8 – volume: 5 start-page: 430 year: 2012 ident: 2021051712064055000_55.9.1438.19 article-title: Integrating noninvasive absolute flow, coronary flow reserve, and ischemic thresholds into a comprehensive map of physiological severity publication-title: JACC Cardiovasc Imaging. doi: 10.1016/j.jcmg.2011.12.014 – ident: 2021051712064055000_55.9.1438.21 doi: 10.1161/01.CIR.88.1.62 – reference: 19380625 - Circulation. 2009 May 5;119(17):2333-42 – reference: 20541718 - JACC Cardiovasc Imaging. 2010 Jun;3(6):623-40 – reference: 23265345 - J Am Coll Cardiol. 2013 Jan 29;61(4):469-77 – reference: 15295413 - J Nucl Cardiol. 2004 Jul-Aug;11(4):440-9 – reference: 19573732 - J Am Coll Cardiol. 2009 Jul 7;54(2):150-6 – reference: 21849402 - J Nucl Med. 2011 Sep;52(9):1490-8 – reference: 19808572 - Circ Cardiovasc Imaging. 2009 Mar;2(2):77-84 – reference: 22733534 - J Nucl Cardiol. 2012 Oct;19(5):1044-59 – reference: 21441533 - J Nucl Med. 2011 Apr;52(4):617-24 – reference: 21816311 - J Am Coll Cardiol. 2011 Aug 9;58(7):740-8 – reference: 8319357 - Circulation. 1993 Jul;88(1):62-9 – reference: 18022104 - J Nucl Cardiol. 2007 Nov-Dec;14(6):782-8 – reference: 8862296 - J Nucl Med. 1996 Oct;37(10):1626-31 – reference: 18022105 - J Nucl Cardiol. 2007 Nov-Dec;14(6):789-98 – reference: 17826322 - J Nucl Cardiol. 2007 Sep-Oct;14(5):688-97 – reference: 22259007 - J Nucl Cardiol. 2012 Feb;19 Suppl 1:S30-7 – reference: 21498538 - J Nucl Med. 2011 May;52(5):726-32 – reference: 20660808 - Circulation. 2010 Aug 10;122(6):603-13 – reference: 22007073 - Circulation. 2011 Nov 15;124(20):2215-24 – reference: 22498334 - JACC Cardiovasc Imaging. 2012 Apr;5(4):430-40 – reference: 19164219 - J Nucl Med. 2009 Feb;50(2):214-9 – reference: 18344426 - J Nucl Med. 2008 Apr;49(4):630-6 |
SSID | ssj0006888 ssj0062072 |
Score | 2.3905604 |
Snippet | Absolute quantitation of myocardial blood flow (MBF) by PET is an established method of analyzing coronary artery disease (CAD) but subject to the various... |
SourceID | proquest pubmed crossref |
SourceType | Aggregation Database Index Database Enrichment Source |
StartPage | 1438 |
SubjectTerms | Aged Cardiovascular disease Coronary Circulation Female Fluorine Radioisotopes Heart attacks Humans Ischemia Male Myocardial Ischemia - physiopathology Nuclear medicine Positron-Emission Tomography - methods Pyridazines Radiometry Stress response Tomography |
Title | Absolute Quantitation of Myocardial Blood Flow in Human Subjects With or Without Myocardial Ischemia Using Dynamic Flurpiridaz F 18 PET |
URI | https://www.ncbi.nlm.nih.gov/pubmed/25071096 https://www.proquest.com/docview/1561352941 https://www.proquest.com/docview/1560098251 https://www.proquest.com/docview/1780504901 |
Volume | 55 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1fb9MwELfKkBAviP8UBjIST0QpSZY4zuMoqwaIaYxO7C2yU5t1lASFVoh-AT4eX4k7O3FTWCfGS9q69inN_Xrn--M7Qp5pjVXGwonPk6jwY6m5z0UU-0oFTIKG35ECI7rvDtj-cfzmJDnp9X51spYWczkolueeK_kfrsIY8BVPyV6Cs44oDMB74C9cgcNw_Sce70pDX2FqZjlvqm2bpJYfoKJqcybkJWame6NZ9R1dG9ZnD9LizGRxfEQvbFWbV0xQ7qx7DWav-jIVnk0qeGU71wMh4My0nk7E0ht5IfcO98YbNrgHWCrZlAlaD98fiuKzsBn1RyD0TKTeOxp8GKwg1jqxQRL5w1PVaFfjUD-dycq6ccWncuEsguFSoYunyS4WoD3WHBph7DK2nI-ThT4aTlZFmTHYmGQ-Y6bzuhPctr5vA9CsI4WxpXtHo4PNGJ-nLaKMYbz6rARiEyyaPMCkV9uwcb0y9x8a0-UxggWFRHJLAk9455bEFXI1ArsFW2q8fb8qX884dx9YFJjWYu7n2pg70nvx1y2t75o2mEJmSzS-SW40rKa7Fpi3SE-Vt8m1lt13yM8Wn7SLT1ppusIZNfikiE86LanBJ23xSRGXtKppg8_uuhaf1OCTNvikHXzSEQ05BXzeJcejvfFw328af_gF2A9zXyYBiAqVChbIJNNRphIZpTrRaYr2OecyiLVIQp5hFVt0Amit0kRIEWKLyXDnHtkqq1I9IFRGjCepFlKCBJJxAeaZYoEWIkxSGIn6JGgfbF40zwGbs8zyjbztk-duyVdbEuaiydstt_JGcnzLQ7TakyiLwz556r4GuY7BOlGqamHmYK1fMD8umIMNSTB0D3PuWyS4O4rQ0Asy9vAyd_uIXF_9I7fJ1rxeqMew6Z7LJwbIvwHlQdWF |
linkProvider | Colorado Alliance of Research Libraries |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Absolute+Quantitation+of+Myocardial+Blood+Flow+in+Human+Subjects+With+or+Without+Myocardial+Ischemia+Using+Dynamic+Flurpiridaz+F+18+PET&rft.jtitle=Journal+of+Nuclear+Medicine&rft.au=Packard%2C+Ren%C3%A9+R.S.&rft.au=Huang%2C+Sung-Cheng&rft.au=Dahlbom%2C+Magnus&rft.au=Czernin%2C+Johannes&rft.date=2014-09-01&rft.issn=0161-5505&rft.eissn=2159-662X&rft.volume=55&rft.issue=9&rft.spage=1438&rft.epage=1444&rft_id=info:doi/10.2967%2Fjnumed.114.141093&rft.externalDBID=n%2Fa&rft.externalDocID=10_2967_jnumed_114_141093 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0161-5505&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0161-5505&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0161-5505&client=summon |